Collegium Pharmaceutical, INC Form 4 insider transactions

Gino Santini, a Director at Collegium Pharmaceutical, Inc., reported the acquisition of 8,700 shares of common stock through the exercise of a stock option.

Director Nancy Lurker of Collegium Pharmaceutical, Inc. acquired 8,741 shares of common stock through the grant of restricted stock units.

Carlos V. Paya, a Director at Collegium Pharmaceutical, Inc., acquired 8,741 shares of common stock through a grant of restricted stock units.

John Gordon Freund, a Director at Collegium Pharmaceutical, Inc., reported transactions involving restricted stock units (RSUs) and stock options.

Director Nancy Lurker sold 4,500 shares of Collegium Pharmaceutical, Inc. common stock at a weighted average price of $35.9691.

David Dieter, EVP & General Counsel of Collegium Pharmaceutical, Inc., reported a transaction involving the sale of 8,840 shares of common stock.

David Dieter, EVP & General Counsel of Collegium Pharmaceutical, sold 13,976 shares of common stock under a pre-arranged 10b5-1 trading plan.

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, sold nearly 50,000 shares of common stock through a pre-arranged trading plan.

Collegium Pharmaceutical's EVP & General Counsel, David Dieter, increased his beneficial ownership through a significant restricted stock unit grant and performance share unit vesting.

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, exercised stock options and subsequently sold 17,600 shares of common stock under a Rule 10b5-1 plan.

Collegium Pharmaceutical Director Rita J. Balice-Gordon sold 3,650 shares of common stock for approximately $47.03 per share under a pre-arranged trading plan.

Collegium Pharmaceutical's President and CEO, Vikram Karnani, reported the disposition of 8,983 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Collegium Pharmaceutical Director John A. Fallon executed a cashless exercise of stock options, acquiring and immediately selling 34,853 shares for a significant profit.

Collegium Pharmaceutical's EVP & CFO, Colleen Tupper, sold 30,000 shares of common stock on November 6, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Collegium Pharmaceutical's EVP and Chief Medical Officer, Thomas B. Smith, sold 17,478 shares of common stock for approximately $672,000.

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Collegium Pharmaceutical Director Gino Santini exercised options and sold shares, adjusting his beneficial ownership.

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, executed a pre-planned sale of 4,861 common shares following an option exercise.

Rubric Capital Management LP and David Rosen reported the sale of 25,000 shares of Collegium Pharmaceutical common stock at a weighted average price of $37.85.

Collegium Pharmaceutical Director John Freund sold 11,659 shares of common stock for approximately $34.36 per share.

John Gordon Freund, a Director and 10% Owner of Collegium Pharmaceutical, Inc., exercised stock options and subsequently sold a portion of his directly held common stock on June 9, 2025.

Director John A. Fallon of Collegium Pharmaceutical, Inc. reports acquisition of shares through restricted stock units.

Director Nancy Lurker reports acquisition of restricted stock units and disposal of common stock.

Director Garen G. Bohlin reports the acquisition of 9,791 shares of Collegium Pharmaceutical common stock through restricted stock units and the disposal of 62,259 shares.

Rita J. Balice-Gordon, a director at Collegium Pharmaceutical, received a grant of restricted stock units representing a contingent right to receive 9,791 shares of common stock.

Director John Freund reports acquisition of Collegium Pharmaceutical shares through restricted stock units and indirect holdings.

Director Gino Santini reports receiving a grant of restricted stock units (RSUs) from Collegium Pharmaceutical.

Director Carlos V. Paya of Collegium Pharmaceutical, Inc. was granted 19,582 restricted stock units (RSUs) on May 15, 2025.

Colleen Tupper, EVP & Chief Financial Officer of Collegium Pharmaceutical, sold shares of common stock on March 20 and 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.

EVP & Chief Commercial Officer of Collegium Pharmaceutical, Scott Dreyer, sold shares of common stock on March 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.